News & Events about Enanta Pharmaceuticals Inc.
Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA Get Rating) have received an average rating of Moderate Buy from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and ...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., Enantas President and Chief Executive Officer, will provide an update across its pipeline of virology programs...
Ticker Report
2 months ago
Enanta Pharmaceuticals (NASDAQ:ENTA Get Rating)s stock had its buy rating reaffirmed by equities research analysts at JMP Securities in a research report issued on Tuesday, Stock Target Advisor reports. They presently have a $96.00 price objective on the biotechnology ...
Business Wire
5 months ago
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral coronavirus protease inhibitor specifically designed for the...
Enanta Pharmaceuticals (NASDAQ:ENTA Get Rating) had its price objective hoisted by JMP Securities from $103.00 to $137.00 in a research report report published on Tuesday , The Fly reports. They currently have a market outperform rating on the biotechnology companys stock. Other equities research ...